Biocon ‘Strongly Denies’ Allegations Of Bribery Amid Reports
Article In The Hindu Makes Claim Over Insulin Aspart Biosimilar Trial Waiver
Executive Summary
India’s Biocon has issued a response after a local English-language daily reported allegations that the company and one of its officials was involved in bribing the Joint Drugs Controller to waive Phase III clinical trial data for its proposed NovoLog (insulin aspart) biosimilar.